New Trials Offer Hope for Type 1 Diabetic Kidney Disease

Published Date: 08 May 2026

At the FSED meeting, investigators highlight SGLT2 inhibitors, finerenone, and GLP-1 or GIP agents as promising strategies to slow kidney decline and cut CV risk in type 1 diabetes.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chromatin organization linked to p53 tumor suppression mechanism

2.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

3.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

4.

New protein target discovered for childhood medulloblastomas

5.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot